Sunpeaks Ventures Announces Addition of Dakota Drug Inc. as Wholesale Distributor of Clotamin
SILVER SPRING, Md., March 9, 2012 /PRNewswire/ — Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the “Company” or “Sunpeaks Ventures”) and its wholly owned subsidiary Healthcare Distribution Specialist, LLC (“HDS”) is pleased to announce that since July 2011 Dakota Drug Inc. has been a wholesale distributor of Clotamin®. Clotamin® is the world’s first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® and other anticoagulants (blood thinners). Founded in 1948, Dakota Drug is an independent full service healthcare distributor dedicated to providing service to pharmacies, retail drug stores and hospitals.
“As we have indicated, the Sunpeaks team is systematically targeting every essential wholesaler with the goal of reaching each small and medium sized pharmacy across the United States,” stated Mackie A. Barch, CEO of Sunpeaks. “It is through these well-known distributors and pharmacies that our brand will continue to grab more market presence. Additional wholesale distribution agreements are expected to be completed in the near future that will expand Clotamin’s availability nationwide.”
Clotamin is now available in North Dakota, South Dakota, Montana, Wyoming, Illinois, Nebraska, Iowa, Wisconsin and Minnesota.
About Sunpeaks Ventures, Inc.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC (“HDS”), is a nationally focused, value-added distributor of specialty drugs and over-the-counter (“OTC”) branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
For additional information, please visit www.sunpeaksventures.com.
Contact: Financial Insights 888-248-8491 or email@example.com
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures’ actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Sunpeaks Ventures, Inc.